Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments

Eli Lilly and Co said on Thursday it will acquire all the shares of Sigilon Therapeutics that it did not own to gain access to experimental cell therapies that can provide longer-term solutions for diabetes patients.